The Board of Cann Global Limited (ASX:CGB) is pleased to provide an update on its recent exclusive distributorship supply contract deal signed with EPCO Foods Co. Ltd in Ho Chi Minh City, Vietnam and its supply of T12 products to COSTCO Australia.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide a summary of the preclinical studies conducted to date for its Gastrointestinal ReProgramming (GaRP) dietary supplement as it targets commencement of a human clinical trial in 2Q 2020.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2019. The Company's cash plus term deposits at the end of the quarter stood at $4.30m
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has come to a mutual agreement with Japan-based manufacturer AGC Inc to terminate their exclusive manufacturing licence and joint venture agreement.
Anatara Lifesciences (ASX:ANR) is pleased to provide an update on the protocol for its clinical trial in irritable bowel syndrome (IBS) for its GaRP dietary supplement.
Anatara Lifesciences (ASX:ANR) is pleased to provide an update on its GaRP dietary supplement preclinical milestones, which is being developed to specifically target two human gastrointestinal disorders, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
The Board of Cann Global Limited (ASX:CGB) is pleased to announce that it has entered into a Heads of Agreement with the South African company Koegas Medicinal Herbs (Pty) Ltd to establish a Joint Venture (CGB to hold 70%) in medicinal Cannabis production and distribution in Africa.
